IGM Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
IGM Biosciences, a clinical-stage biotechnology company, announced that CEO Fred Schwarzer will present virtually at the 40th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
IGM Biosciences, a clinical-stage biotechnology company, announced that CEO Fred Schwarzer will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 10:30 a.m. EST. The presentation will be accessible via a live webcast on the Company’s website, with a replay available for 30 days afterward. IGM Biosciences focuses on developing engineered IgM antibodies, addressing manufacturing and engineering challenges to enhance therapeutic applications compared to IgG antibodies.
Details
News Market Reaction – IGMS
The recorded move for IGMS in the trading session of this news was -5.66%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 10:30 a.m. EST.
A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company’s website for 30 days following the presentation.
About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.
Contact
Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.